NCT05382364 2026-03-12Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)PfizerPhase 1 Active not recruiting25 enrolled
NCT04430738 2026-02-24Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersSeagen Inc.Phase 2 Active not recruiting40 enrolled 67 charts